Source-grounded facts extracted from CARDINAL HEALTH INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CARDINAL HEALTH INC reported FY26 results: EPS $10.70 to $10.80. Guidance raised.
“Cardinal Health is raising and narrowing its fiscal year 2026 guidance for non-GAAP diluted EPS attributable to Cardinal Health, Inc. to a range of $10.70 to $10.80 (+30% to +31% growth).”
CARDINAL HEALTH INC reported Q3 FY26 results: revenue $60.9 billion, net income $750 million, EPS $3.17.
“Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2026 revenues of $60.9 billion, an increase of 11% from the third quarter of fiscal year 2025. Third quarter GAAP operating earnings decreased 30% to $509 million and GAAP diluted earnings per share (EPS) decreased 20% to $1.69”
CARDINAL HEALTH INC incurred senior notes of $600,000,000 aggregate principal amount of 4.500% Notes due 2030 and $400,000,000 aggregate principal amount of 5.150% N with The Bank of New York Mellon Trust Company, N.A. at 4.500% and 5.150% maturing 2030 and 2035.
“On August 27, 2025, Cardinal Health, Inc. (the “Company”) completed a public offering of $600,000,000 aggregate principal amount of 4.500% Notes due 2030 (the “2030 Notes”) and $400,000,000 aggregate principal amount of 5.150% Notes due 2035 (the “2035 Notes” and, together with the 2030 Notes, the “Notes”).”
Sudhakar Ramakrishna was elected as Director at CARDINAL HEALTH INC.
“On March 7, 2025, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Musslewhite and Sudhakar Ramakrishna to the Board, effective immediately.”
Robert W. Musslewhite was elected as Director at CARDINAL HEALTH INC.
“On March 7, 2025, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Musslewhite and Sudhakar Ramakrishna to the Board, effective immediately.”
Sujatha Chandrasekaran departed as Director at CARDINAL HEALTH INC.
“On September 6, 2024 and September 8, 2024, respectively, Steven K. Barg and Sujatha Chandrasekaran, both members of the Board of Directors (the “Board”) of Cardinal Health, Inc. (the "Company") since 2022, informed the Company that they have decided not to stand for re-election to the Board when their terms expire at the 2024 annual meeting of shareholders.”
Steven K. Barg departed as Director at CARDINAL HEALTH INC.
“On September 6, 2024 and September 8, 2024, respectively, Steven K. Barg and Sujatha Chandrasekaran, both members of the Board of Directors (the “Board”) of Cardinal Health, Inc. (the "Company") since 2022, informed the Company that they have decided not to stand for re-election to the Board when their terms expire at the 2024 annual meeting of shareholders.”
CARDINAL HEALTH INC reported third quarter fiscal year 2024 results: revenue $54.9 billion, net income $258 million, EPS $1.05. Guidance raised.
“Cardinal Health Reports Third Quarter Fiscal Year 2024 Results and Raises Fiscal Year 2024 Non-GAAP EPS Guidance • Revenue increased 9% to $54.9 billion • GAAP 1 operating earnings were $367 million; GAAP diluted EPS was $1.05 • Non-GAAP operating earnings increased 10% to $666 million; non-GAAP diluted EPS increased 20% to $2.08 • Fiscal year 2024 non-GAAP EPS guidance 2 raised and narrowed to $7.30 to $7.40, from $7.20 to $7.35 • Company provides preliminary fiscal year 2025 non-GAAP EPS guidance of at least $7.50”
Robert W. Azelby was elected as Director at CARDINAL HEALTH INC.
“On February 28, 2024, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Azelby to the Board, effective March 1, 2024, to serve until the 2024 annual meeting of shareholders and until his successor is elected and qualified or until his earlier resignation, removal from office, or death.”
CARDINAL HEALTH INC reported the quarter ended December 31, 2023 results: revenue $57.4 billion, EPS $1.43. Guidance raised.
“report. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE Cardinal Health Reports Second Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook • Revenue increased 12% to $57.4 billion • GAAP 1 operating earnings were $482 million; GAAP diluted EPS was $1.43 • Non-GAAP operating earnings increased 20% to $562 million; non-GAAP diluted EPS increased 38% to $1.82”
CARDINAL HEALTH INC reported fiscal year 2024 results: EPS high end of $6.75 to $7.00 range. Guidance raised.
“Updated fiscal 2024 non-GAAP diluted EPS guidance to high end of $6.75 to $7.00 range”
CARDINAL HEALTH INC shareholders rejected Shareholder proposal to adopt a policy requiring shareholder ratification of excessive termination pay at the 2023-11-15 meeting.
“Proposal 6 . The shareholders did not approve the shareholder proposal to adopt a policy requiring shareholder ratification of excessive termination pay, and voted as follows: For Against Abstained Broker Non-Votes 19,084,904 180,422,143 646,712 19,854,118”
CARDINAL HEALTH INC shareholders rejected Shareholder proposal to adopt a policy requiring executives to retain significant stock at the 2023-11-15 meeting.
“Proposal 5 . The shareholders did not approve the shareholder proposal to adopt a policy requiring executives to retain significant stock, and voted as follows: For Against Abstained Broker Non-Votes 64,964,097 133,971,250 1,218,412 19,854,118”
CARDINAL HEALTH INC shareholders approved Non-binding advisory vote on frequency of future say-on-pay votes at the 2023-11-15 meeting.
“Proposal 4 . The shareholders voted, on a non-binding advisory basis, in support of holding future advisory votes to approve the compensation of the Company's named executive officers ("say-on-frequency" vote) every year as follows: One Year Two Years Three Years Abstained Broker Non-Votes 196,230,933 302,493 3,230,365 398,968 19,854,118”
CARDINAL HEALTH INC shareholders approved Non-binding advisory vote on compensation of named executive officers (say-on-pay) at the 2023-11-15 meeting.
“Proposal 3 . The shareholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers ("say-on-pay" vote), and voted as follows: For Against Abstained Broker Non-Votes 182,671,067 16,863,757 618,935 19,854,118”
CARDINAL HEALTH INC shareholders approved Ratification of appointment of Ernst & Young LLP as independent auditor for fiscal year ending June 30, 2024 at the 2023-11-15 meeting.
“Proposal 2 . The shareholders ratified the appointment of Ernst & Young LLP as the Company's independent auditor for the fiscal year ending June 30, 2024, and voted as follows: For Against Abstained Broker Non-Votes 209,450,694 10,345,728 211,455 —”
CARDINAL HEALTH INC shareholders approved Election of 11 nominees to the Board of Directors at the 2023-11-15 meeting.
“Proposal 1 . The shareholders elected the 11 nominees listed below to the Company's Board of Directors, each to serve until the 2024 Annual Meeting of Shareholders and until their successor is duly elected and qualified or until their earlier resignation, removal from office or death, and voted as follows:”
CARDINAL HEALTH INC reported the quarter ended September 30, 2023 results: revenue $54.8 billion, net income $5 million, EPS $0.02. Guidance raised.
“report. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE Cardinal Health Reports First Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook • Revenue increased 10% to $54.8 billion • GAAP 1 operating loss was $14 million and GAAP diluted EPS was $0.02, driven by a Medical segment goodwill impairment • Non-GAAP operating earnings increased 35% to $571”
CARDINAL HEALTH INC amended Fifth Amended and Restated Receivables Purchase Agreement with Wells Fargo Bank, N.A., Liberty Street Funding LLC, The Bank of Nova Scotia, PNC Bank, National Association, Bank of America, National Association, Victory Receivables Corporation, MUFG Bank, LTD valued at $1.0 billion (effective 2023-09-01).
“On September 1, 2023, Cardinal Health Funding, LLC (“Funding”), a receivables financing subsidiary of Griffin Capital, LLC (“Griffin Capital”), Cardinal Health 23 Funding, LLC (“CH-23 Funding”), a receivables financing subsidiary of Cardinal Health 23, LLC (“CH-23”), Griffin Capital, a receivables financing indirect subsidiary of Cardinal Health, Inc. (the “Company”), as original servicer, CH-23, a receivables financing indirect subsidiary of the Company, as servicer, Wells Fargo Bank, N.A. (“WF”), Liberty Street Funding LLC (“Liberty Street”), The Bank of Nova Scotia (“BNS”), PNC Bank, National Association (“PNC”), Bank of America, National Association (“BofA”), Victory Receivables Corporation (“Victory”) and MUFG Bank, LTD (“MUFG”) entered into a Fifth Amended and Restated Receivables Purchase Agreement (the “Amendment and Restatement”).”
CARDINAL HEALTH INC reported the quarter and fiscal year ended June 30, 2023 results: revenue $205.0 billion, net income $261 million, EPS $1.00. Guidance raised.
“RELEASE Cardinal Health Reports Fourth Quarter and Full Year Results for Fiscal Year 2023 at High End of Investor Day Guidance • Fourth quarter revenue increased 13% to $53.5 billion • Fourth quarter GAAP 1 operating earnings were $137 million and GAAP diluted loss per share was $0.25 • Fourth quarter non-GAAP operating earnings increased 24% to $560 million”
Carrie S. Cox departed as Director at CARDINAL HEALTH INC.
“On August 10, 2023, Carrie S. Cox, a member of the Board of Directors (the “Board”) of the Company since 2009, informed the Company that she has decided not to stand for re-election to the Board when her term expires at the 2023 annual meeting of shareholders.”
CARDINAL HEALTH INC: The board adopted an amendment and restatement of the Company's Restated Code of Regulations to clarify and implement procedural requirements for shareholder nominations in light of the universal proxy rules adopted by the SEC (effective 2023-05-11).
“On May 11, 2023, the board of directors of Cardinal Health, Inc. (the "Company") adopted an amendment and restatement of the Company's Restated Code of Regulations (the "Regulations"), effective immediately. The amendments clarify and implement certain procedural requirements for the Company’s shareholders proposing director nominations for consideration at the Company’s annual or special meetings of shareholders in light of the “universal proxy” rules adopted by the U.S. Securities and Exchange Commission as Rule 14a-19 of the Securities Exchange Act of 1934, as amended.”
CARDINAL HEALTH INC reported third quarter fiscal year 2023 (quarter ended March 31, 2023) results: revenue $50.5 billion, net income $345 million, EPS $1.34. Guidance raised.
“Today reported third quarter fiscal year 2023 revenues of $50.5 billion, an increase of 13% from the third quarter of fiscal year 2022. Third quarter GAAP operating earnings were $572 million and GAAP diluted earnings per share (EPS) were $1.34.”
CARDINAL HEALTH INC amended First Amendment with Elliott Associates, L.P., Elliott International, L.P., Elliott International Capital Advisors Inc. (effective 2023-05-03).
“On May 3, 2023, Cardinal Health, Inc., (the “Company”) entered into a First Amendment (the “Amendment”) to the Cooperation Agreement (the “Cooperation Agreement”) dated September 5, 2022 by and among Elliott Associates, L.P., Elliott International, L.P. and Elliott International Capital Advisors Inc. and the Company.”
CARDINAL HEALTH INC entered into Third Amended and Restated Five-Year Credit Agreement with JPMorgan Chase Bank, N.A. valued at $2.0 billion (effective 2023-02-27).
“On February 27, 2023, Cardinal Health, Inc. (the “Company”), JPMorgan Chase Bank, N.A., as Administrative Agent, Joint Lead Arranger and Joint Book Manager, Bank of America, N.A. and Wells Fargo Bank, National Association as Syndication Agents, Barclays Bank PLC, Deutsche Bank Securities, Inc., Goldman Sachs Bank USA, HSBC Bank USA, N.A., and MUFG Bank, Ltd. as Documentation Agents, and BofA Securities, Inc. and Wells Fargo Securities, LLC, as Joint Lead Arrangers and Joint Book Managers, entered into a Third Amended and Restated Five-Year Credit Agreement (the “Credit Agreement”).”
CARDINAL HEALTH INC reported results: revenue $51.5 billion, net income GAAP diluted loss per share was $0.50, EPS $1.32. Guidance raised.
“Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2023 revenues of $51.5 billion, an increase of 13% from the second quarter of fiscal year 2022. Second quarter GAAP operating loss was $119 million due to a non-cash, pre-tax goodwill impairment of $709 million related to the Medical segment. GAAP diluted loss per share was $0.50, primarily due to this impairment, net of tax effects. Second quarter non-GAAP operating earnings of $467 million were in-line with the second quarter of last year. Non-GAAP diluted earnings per share (EPS) increased 4% to $1.32, due to lower interest expense and a lower share count, partially offset by a higher non-GAAP effective tax rate.”
Patricia M. English departed as Chief Financial Officer (Interim) at CARDINAL HEALTH INC.
“Mr. Alt will succeed Patricia M. English, who will continue to serve as interim CFO until February 10, 2023.”
Aaron E. Alt was elected as Chief Financial Officer at CARDINAL HEALTH INC.
“On December 16, 2022, the Board of Directors of Cardinal Health, Inc. (the “Company”) elected Aaron E. Alt, 51, as Chief Financial Officer (“CFO”) of the Company, effective February 10, 2023.”
CARDINAL HEALTH INC shareholders approved Advisory Vote on Executive Compensation at the 2022-11-09 meeting.
“Proposal 3 . The shareholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, and voted as follows: For Against Abstained Broker Non-Votes 184,983,772 18,266,030 946,572 25,132,179”
CARDINAL HEALTH INC shareholders approved Ratification of Appointment of Ernst & Young LLP as Independent Auditor at the 2022-11-09 meeting.
“Proposal 2 . The shareholders ratified the appointment of Ernst & Young LLP as the Company's independent auditor for the fiscal year ending June 30, 2023, and voted as follows: For Against Abstained Broker Non-Votes 220,482,418 8,302,561 543,574 —”
CARDINAL HEALTH INC shareholders approved Election of Directors at the 2022-11-09 meeting.
“Proposal 1 . The shareholders elected the 13 nominees listed below to the Company's Board of Directors, each to serve until the 2023 Annual Meeting of Shareholders and until their successor is duly elected and qualified or until their earlier resignation, removal from office or death, and voted as follows: Nominee For Against Abstained Broker Non-Votes Steven K. Barg 202,651,413 846,605 698,356 25,132,179 Michelle M. Brennan 202,664,643 849,411 682,320 25,132,179 Sujatha Chandrasekaran 202,665,819 837,984 692,571 25,132,179 Carrie S. Cox 175,425,242 28,029,748 741,384 25,132,179 Bruce L. Downey 191,511,168 11,918,084 767,122 25,132,179 Sheri H. Edison 202,223,804 1,285,528 687,042 25,132,179 David C. Evans 200,751,856 2,747,834 696,684 25,132,179 Patricia A. Hemingway Hall 198,435,528 5,013,088 747,758 25,132,179 Jason M. Hollar 202,218,082 1,285,541 692,751 25,132,179 Akhil Johri 202,136,509 1,363,909 695,956 25,132,179 Gregory B. Kenny 189,660,047 13,842,463 693,864 25,132,179 Nancy”
CARDINAL HEALTH INC reported the quarter ended September 30, 2022 results: revenue $49.6 billion, net income $110 million, EPS $0.40. Guidance reaffirmed.
“Cardinal Health Reports First Quarter Fiscal 2023 Results • Revenue increased 13% to $49.6 billion • GAAP 1 operating earnings were $137 million, GAAP diluted EPS were $0.40 • Non-GAAP operating earnings decreased 20% to $423 million due to a decline in Medical segment profit, partially offset by an increase in Pharmaceutical segment profit; non-GAAP diluted EPS decreased 7% to $1.20 • Company reaffirmed fiscal year 2023 non-GAAP EPS guidance”
Victor L. Crawford departed as Chief Executive Officer, Pharmaceutical Segment at CARDINAL HEALTH INC.
“On September 8, 2022, Cardinal Health, Inc. (the “Company”) announced that Victor L. Crawford will cease to serve as Chief Executive Officer, Pharmaceutical Segment effective September 19, 2022.”
Christine Mundkur was appointed as Director at CARDINAL HEALTH INC.
“Director Appointments Pursuant to the Cooperation Agreement, each of the New Directors was appointed to the Board effective September 6, 2022.”
Sujatha Chandrasekaran was appointed as Director at CARDINAL HEALTH INC.
“Director Appointments Pursuant to the Cooperation Agreement, each of the New Directors was appointed to the Board effective September 6, 2022.”
Michelle Brennan was appointed as Director at CARDINAL HEALTH INC.
“Director Appointments Pursuant to the Cooperation Agreement, each of the New Directors was appointed to the Board effective September 6, 2022.”
Steven Barg was appointed as Director at CARDINAL HEALTH INC.
“Director Appointments Pursuant to the Cooperation Agreement, each of the New Directors was appointed to the Board effective September 6, 2022.”
Michael C. Kaufmann departed as Director at CARDINAL HEALTH INC.
“Mr. Kaufmann will resign as a member of the Board on September 1, 2022.”
Michael C. Kaufmann departed as Chief Executive Officer at CARDINAL HEALTH INC.
“Mr. Hollar will succeed current CEO Michael C. Kaufmann, who will depart from the Company on September 1, 2022.”
Mary C. Scherer was elected as Senior Vice President and Chief Accounting Officer at CARDINAL HEALTH INC.
“On August 10, 2022, the Board also elected Mary C. Scherer, 54, as Senior Vice President and Chief Accounting Officer, effective September 1, 2022.”
Patricia M. English was elected as Interim Chief Financial Officer at CARDINAL HEALTH INC.
“On August 10, 2022, the Board also elected Patricia M. English, 43, as Interim CFO of the Company, effective September 1, 2022.”
Jason M. Hollar was elected as Director at CARDINAL HEALTH INC.
“The Board also elected Mr. Hollar as a director effective August 11, 2022.”
Jason M. Hollar was elected as Chief Executive Officer at CARDINAL HEALTH INC.
“On August 10, 2022, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Jason M. Hollar, 49, as Chief Executive Officer (“CEO”) of the Company, effective September 1, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.